Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome

被引:71
作者
Hall, Marcia [1 ]
Savvatis, Konstantinos [2 ,3 ]
Nixon, Katherine [4 ,5 ]
Kyrgiou, Maria [4 ,5 ]
Hariharan, Kuhan [1 ]
Padwick, Malcolm [6 ]
Owens, Owen [6 ]
Cunnea, Paula [4 ,5 ]
Campbell, Jeremy [7 ]
Farthing, Alan [4 ,5 ]
Stumpfle, Richard [7 ]
Vazquez, Ignacio [1 ]
Watson, Neale [8 ]
Krell, Jonathan [4 ,5 ]
Gabra, Hani [4 ,5 ,9 ]
Rustin, Gordon [1 ]
Fotopoulou, Christina [4 ,5 ,7 ]
机构
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Barts Heart Ctr, Inherited Cardiovasc Dis Unit, London, England
[3] Queen Mary Univ, William Harvey Res Inst, London, England
[4] Imperial Coll London, Dept Surg & Canc, London, England
[5] Imperial Coll NHS Trust, West London Gynecol Canc Ctr, London, England
[6] WHH NHS Trust, West Hertfordshire Gynaecol Canc Ctr, Watford, England
[7] Hammersmith Hosp, Imperial Coll Healthcare NHS Trust, Ctr Perioperat Med & Crit Care Res, Dept Anaesthet, Ham House, London, England
[8] Hillingdon Hosp, Dept Gynaecol, Uxbridge, Middx, England
[9] AstraZeneca, IMED Biotech Unit, Early Clin Dev, Cambridge, England
关键词
COMPLEX SURGERY; SURVIVAL; ONCOLOGY; SOCIETY; WOMEN;
D O I
10.1245/s10434-019-07516-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background This study aimed to compare the outcomes of two distinct patient populations treated within two neighboring UK cancer centers (A and B) for advanced epithelial ovarian cancer (EOC). Methods A retrospective analysis of all new stages 3 and 4 EOC patients treated between January 2013 and December 2014 was performed. The Mayo Clinic surgical complexity score (SCS) was applied. Cox regression analysis identified the impact of treatment methods on survival. Results The study identified 249 patients (127 at center A and 122 in centre B) without significant differences in International Federation of Gynecology and Obstetrics (FIGO) stage (FIGO 4, 29.7% at centers A and B), Eastern Cooperative Oncology Group (ECOG) performance status (ECOG < 2, 89.9% at centers A and B), or histology (serous type in 84.1% at centers A and B). The patients at center A were more likely to undergo surgery (87% vs 59.8%; p < 0.001). The types of chemotherapy and the patients receiving palliative treatment alone were equivalent between the two centers (3.6%). The median SCS was significantly higher at center A (9 vs 2; p < 0.001) with greater tumor burden (9 vs 6 abdominal fields involved; p < 0.001), longer median operation times (285 vs 155 min; p < 0.001), and longer hospital stays (9 vs 6 days; p < 0.001), but surgical morbidity and mortality were equivalent. The independent predictors of reduced overall survival (OS) were non-serous histology (hazard ratio [HR], 1.6; 95% confidence interval [CI] 1.04-2.61), ECOG higher than 2 (HR, 1.9; 95% CI 1.15-3.13), and palliation alone (HR, 3.43; 95% CI 1.51-7.81). Cytoreduction, of any timing, had an independent protective impact on OS compared with chemotherapy alone (HR, 0.31 for interval surgery and 0.39 for primary surgery), even after adjustment for other prognostic factors. Conclusions Incorporating surgery into the initial EOC management, even for those patients with a greater tumor burden and more disseminated disease, may require more complex procedures and more resources in terms of theater time and hospital stay, but seems to be associated with a significant prolongation of the patients overall survival compared with chemotherapy alone.
引用
收藏
页码:2943 / 2951
页数:9
相关论文
共 25 条
[11]   British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice [J].
Fotopoulou, Christina ;
Hall, Marcia ;
Cruickshank, Derek ;
Gabra, Hani ;
Ganesan, Raji ;
Hughes, Cathy ;
Kehoe, Sean ;
Ledermann, Jonathan ;
Morrison, Jo ;
Naik, Raj ;
Rolland, Phil ;
Sundar, Sudha .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2017, 213 :123-139
[12]   Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective [J].
Fotopoulou, Christina ;
Sehouli, Jalid ;
Aletti, Giovanni ;
Harter, Philipp ;
Mahner, Sven ;
Querleu, Denis ;
Chiva, Luis ;
Gabra, Hani ;
Colombo, Nicoletta ;
du Bois, Andreas .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) :587-+
[13]   Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities [J].
Fotopoulou, Christina ;
Jones, Benjamin P. ;
Savvatis, Konstantinos ;
Campbell, Jeremy ;
Kyrgiou, Maria ;
Farthing, Alan ;
Brett, Stephen ;
Roux, Rene ;
Hall, Marcia ;
Rustin, Gordon ;
Gabra, Hani ;
Jiao, Long ;
Stumpfle, Richard .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 294 (03) :607-614
[14]   Patient-Reported Outcomes After Extensive (Ultraradical) Surgery for Ovarian Cancer Results From a Prospective Longitudinal Feasibility Study [J].
Hoo, San Soo ;
Marriott, Natalie ;
Houlton, Aimee ;
Nevin, James ;
Balega, Janos ;
Singh, Kavita ;
Yap, Jason ;
Sethuram, Ramya ;
Elattar, Ahmed ;
Luesley, David ;
Kehoe, Sean ;
Sundar, Sudha .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) :1599-1607
[15]   Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer: An Analysis of GOG 182 [J].
Horowitz, Neil S. ;
Miller, Austin ;
Rungruang, Bunja ;
Richard, Scott D. ;
Rodriguez, Noah ;
Bookman, Michael A. ;
Hamilton, Chad A. ;
Krivak, Thomas C. ;
Maxwell, G. Larry .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (08) :937-+
[16]   TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO-OVAR OP7). [J].
Mahner, Sven ;
Heitz, Florian ;
Burges, Alexander ;
Reuss, Alexander ;
Kraemer, Bernhard ;
Schmalfeldt, Barbara ;
Sehouli, Jalid ;
Lampe, Bjoern ;
Schnelzer, Andreas ;
Wimberger, Pauline ;
Fotopoulou, Christina ;
Guyon, Frederic ;
Lecuru, Fabrice ;
Querleu, Denis ;
Greggi, Stefano ;
Colombo, Nicoletta ;
Aletti, Giovanni Damiano ;
Harter, Philipp ;
Du Bois, Andreas .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[17]   Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer [J].
Phillips, Andrew ;
Balega, Janos ;
Nevin, James ;
Singh, Kavita ;
Elattar, Ahmed ;
Kehoe, Sean ;
Sundar, Sudha .
GYNECOLOGIC ONCOLOGY, 2017, 146 (01) :94-100
[18]   European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery [J].
Querleu, Denis ;
Planchamp, Francois ;
Chiva, Luis ;
Fotopoulou, Christina ;
Barton, Desmond ;
Cibula, David ;
Aletti, Giovanni ;
Carinelli, Silvestro ;
Creutzberg, Carien ;
Davidson, Ben ;
Harter, Philip ;
Lundvall, Lene ;
Marth, Christian ;
Morice, Philippe ;
Rafii, Arash ;
Ray-Coquard, Isabelle ;
Rockall, Andrea ;
Sessa, Cristiana ;
van der Zee, Ate ;
Vergote, Ignace ;
du Bois, Andreas .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (07) :1354-1363
[19]   Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care [J].
Rodriguez Gomez-Hidalgo, Natalia ;
Alejandra Martinez-Cannon, Bertha ;
Nick, Alpa M. ;
Lu, Karen H. ;
Sood, Anil K. ;
Coleman, Robert L. ;
Ramirez, Pedro T. .
GYNECOLOGIC ONCOLOGY, 2015, 137 (03) :553-558
[20]   Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial [J].
Rustin, Gordon J. S. ;
van der Burg, Maria E. L. ;
Griffin, Clare L. ;
Guthrie, David ;
Lamont, Alan ;
Jayson, Gordon C. ;
Kristensen, Gunnar ;
Mediola, Cesar ;
Coens, Corneel ;
Qian, Wendi ;
Parmar, Mahesh K. B. ;
Swart, Ann Marie .
LANCET, 2010, 376 (9747) :1155-1163